![4-[[9-氯-7-(2-氟-6-甲氧基苯基)-5H-嘧啶并[5,4-D][2]苯并氮杂卓-2-基]氨基]-2-甲氧基苯甲酸](https://stcdn.activebiopharma.com/active/ABP000944.png)
Chemical Name : 4-[[9-氯-7-(2-氟-6-甲氧基苯基)-5H-嘧啶并[5,4-D][2]苯并氮杂卓-2-基]氨基]-2-甲氧基苯甲酸
CAS : 1028486-01-2
溶解度:Soluble in DMSO (5mg/ml)
储存条件:-20C 2 years
生物活性
Treat Cystic Fibrosis and Duchenne and Becker Muscular Dystrophy (nmDMD/BMD). It shows promising result in Phase 2. Orally bioavailable 284 D-1,2,4-oxadiazole. Promotes readthrough of premature translation termination codons. Targets genetic disorders caused by nonsense mutations. Shows no concomitant effects on normal termination or mRNA decay.
参考文献
1��PTC124 targets genetic disorders caused by nonsense mutations: E.M. Welch, et al.; Nature 447, 87 (2007) 2��PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model: M. Du, et al.; PNAS 105, 2064 (2008) 3��Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial: E. Kerem, et al.; Lancet 372, 719 (2008)
PHA-680632 /PHA680632
398493-79-3
(3AS,4R,9BR)-1,2,3,3A,4,9B-六氢-4-(4-羟基苯基)环戊并[C][1]苯并吡喃-8-醇
533884-09-2
N-[4-[[3-(2-氨基-4-嘧啶基)-2-吡啶基]氧基]苯基]-4-(4-甲基-2-噻吩基)-1-酞嗪胺
945595-80-2
佛司可林
942918-07-2